Page 5 - Pharma Industry

Govt to closely monitor price hikes of drugs outside essential list

The NPPA will ensure drug companies do not exceed the 10% annual price increase limit on non-essential medicines

India-UK trade deal: Med device firms cautious about country of origin

The UK-India Free Trade Agreement is expected to boost trade in pharmaceuticals and medical devices, though industry players remain cautious about the impact of country of origin rules

Dr Reddy Laboratories Q1 profit up 2%, posts best ever quarterly revenue

Dr Reddy's reported Rs 1,417 crore net profit in Q1 FY26, driven by new launches and price hikes; firm outlines global semaglutide strategy and GLP-1 product pipeline

Results preview: Pharma firms stare at muted earnings growth for Q1

Indian pharma firms are set to post modest Q1FY26 earnings, with Revlimid erosion impacting US revenues and domestic growth moderating in chronic therapies

PLI scheme for bulk drugs led to import savings of ₹1,362 cr: Govt to RS

Imports of pharma raw materials worth Rs 1,362 crore have been avoided till March 2025 due to the creation of domestic manufacturing capacity for 25 identified items under the production-linked incentive scheme for bulk drugs, Parliament was informed on Tuesday. In a written reply to Rajya Sabha, Minister of State for Chemicals and Fertilisers, Anupriya Patel said that as of March 2025, against an investment commitment of Rs 3,938.5 crore over the period of six years, investment of Rs 4,570 crore has already been made under the PLI Scheme for Bulk Drugs. "As a result of the scheme, cumulative sales of Rs 1,817 crore have been reported over the period from the beginning of the scheme till March 2025, including exports of Rs 455 crore, thereby avoiding imports worth Rs 1,362 crore and creation of domestic manufacturing capacity for 25 identified KSMs/DIs/APIs," she stated. The PLI Scheme for Bulk Drugs has a total budgetary outlay of Rs 6,940 crore and aims to avoid disruption in supp

Abu Dhabi Investment Authority buys 3% stake in Meril for $200 million

Abu Dhabi Investment Authority acquires a 3% stake in Meril for $200 million, valuing the Gujarat-based medical devices maker at $6.6 billion. The deal is pending approval from CCI

Generic glut leads to numerous price actions on diabetes medications

Government may fix retail prices for empagliflozin combinations as generic versions flood the market following the drug's patent expiry, causing price drops

Zydus Lifesciences gets USFDA nod for its painkiller Celecoxib capsules

The company said that the medicine is used to treat pain or inflammation caused by many conditions such as arthritis, ankylosing spondylitis, and menstrual pain

Anti-obesity drug war heats up as Wegovy and Mounjaro boost sales

India's Rs 628-crore anti-obesity market sees heightened competition as Wegovy and Mounjaro post strong sales amid rising obesity and growing doctor awareness

Sun Pharma launches Leqselvi in US after patent settlement with Incyte Corp

Sun Pharma will pay Incyte an upfront fee and royalties to market Leqselvi in the US for alopecia areata until patent expiry in FY26 following a litigation settlement

Wockhardt exits US generics biz, to focus on innovative portfolio

Wockhardt exits the US generics market after years of losses, shifting focus to new antibiotic drug discovery and biologicals, including insulin, to create long-term value.

Anthem Biosciences expands manufacturing capacity ahead of ₹3,395-cr IPO

CRDMO firm Anthem Biosciences expands peptide and API production, with Unit 4 under development, as it prepares for a Rs 3,395-crore IPO opening on July 14

Trump threatens 200% pharma, 50% copper tariffs: What it means for India

As trade tensions escalate under Donald Trump, India finds itself in the crosshairs once again. Donald Trump's proposed duties target two of India's biggest export sectors - pharmaceuticals and copper

India's pharma exports to US surged in March amid tariff concerns

India's pharma exports saw a significant rise in March, driven by fears of impending US tariffs. Industry experts anticipate impact of potential reciprocal tariffs on India's future export strategy

GMP, NSQ compliance: MSME pharmaceutical companies seek financial aid

Pharma MSMEs seek Rs 50 crore handholding and extension for GMP compliance under revised Schedule M, citing challenges in adhering to regulatory and quality standards

HC-ordered expert panel for weight loss drug may be set up by mid-July

A Delhi HC directive to examine unregulated use of weight loss drugs may lead to a CDSCO expert panel by mid-July, possibly led by DCGI with pharma and govt representation

Pharma GCCs tap artificial intelligence to fast-track drug discovery

They are not just cutting down drug development time, but also the cost involved in it. AI is reshaping how drugs and therapies are developed

Lupin carves out consumer healthcare biz into wholly owned subsidiary

The carve-out will be effective from 1 July 2025, according to the company's regulatory filing on the exchanges.

KKR's JB Chemicals exit cements its strong healthcare track record

The sale of its 46.39 per cent stake in JB Chemicals to Torrent Pharmaceuticals comes over four years after KKR acquired control of the company in 2020

Biological E to make HPV9 vaccine under licensing pact with Recbio

BE to produce and commercialise Recbio's nine-valent HPV vaccine in India and global markets, including participation in UNICEF and PAHO tenders